{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T13:27:16Z","timestamp":1770038836231,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.vaccine.2017.02.029","type":"journal-article","created":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T08:48:24Z","timestamp":1488185304000},"page":"1683-1691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Recombinant BCG expressing a PspA-PdT fusion protein protects mice against pneumococcal lethal challenge in a prime-boost strategy"],"prefix":"10.1016","volume":"35","author":[{"given":"Cibelly","family":"Goulart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dunia","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex I.","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Malley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana C.C.","family":"Leite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.02.029_b0005","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1016\/j.vaccine.2012.04.093","article-title":"Pneumococcal vaccines WHO position paper \u2013 2012 \u2013 recommendations","volume":"30","author":"WHO","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.029_b0010","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","article-title":"Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates","volume":"374","author":"O'Brien","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.02.029_b0015","doi-asserted-by":"crossref","first-page":"e1001517","DOI":"10.1371\/journal.pmed.1001517","article-title":"Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites","volume":"10","author":"Feikin","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2017.02.029_b0020","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1086\/652440","article-title":"The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes","volume":"50","author":"Lehmann","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.02.029_b0025","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.1128\/AAC.03344-14","article-title":"Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States","volume":"58","author":"Richter","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2017.02.029_b0030","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0882-4010(86)90038-0","article-title":"Analysis of a surface protein of Streptococcus pneumoniae recognised by protective monoclonal antibodies","volume":"1","author":"McDaniel","year":"1986","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2017.02.029_b0035","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1128\/IAI.67.9.4720-4724.1999","article-title":"Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae","volume":"67","author":"Tu","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.02.029_b0040","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/IAI.72.1.114-122.2004","article-title":"Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface","volume":"72","author":"Ren","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.02.029_b0045","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1128\/IAI.01199-09","article-title":"The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis","volume":"78","author":"Daniels","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.02.029_b0050","doi-asserted-by":"crossref","first-page":"e27102","DOI":"10.1371\/journal.pone.0027102","article-title":"Maternal immunization with pneumococcal surface protein A protects against pneumococcal infections among derived offspring","volume":"6","author":"Kono","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.02.029_b0055","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1128\/IAI.71.3.1033-1041.2003","article-title":"Regions of PspA\/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model","volume":"71","author":"Roche","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.02.029_b0060","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0264-410X(99)00530-7","article-title":"Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules","volume":"18","author":"Nabors","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.029_b0065","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1128\/iai.41.3.1212-1216.1983","article-title":"Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity, and migration by pneumolysin","volume":"41","author":"Paton","year":"1983","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.02.029_b0070","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1128\/iai.43.3.1085-1087.1984","article-title":"Activation of human complement by the pneumococcal toxin pneumolysin","volume":"43","author":"Paton","year":"1984","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.02.029_b0075","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1073\/pnas.0435928100","article-title":"Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection","volume":"100","author":"Malley","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.02.029_b0080","doi-asserted-by":"crossref","first-page":"e1001191","DOI":"10.1371\/journal.ppat.1001191","article-title":"Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4","volume":"6","author":"McNeela","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2017.02.029_b0085","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1128\/iai.62.12.5683-5688.1994","article-title":"Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae","volume":"62","author":"Alexander","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.02.029_b0090","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1128\/iai.63.5.1969-1974.1995","article-title":"Effect of defined point mutations in the pneumolysin gene on the virulence of Streptococcus pneumoniae","volume":"63","author":"Berry","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.02.029_b0095","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1128\/IAI.06348-11","article-title":"Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury","volume":"80","author":"Salha","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.02.029_b0100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.vaccine.2012.11.005","article-title":"Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults","volume":"31","author":"Kamtchoua","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.029_b0105","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.vaccine.2014.03.066","article-title":"Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial","volume":"32","author":"Prymula","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.029_b0110","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1016\/j.vaccine.2014.02.052","article-title":"Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I\/II randomized clinical study","volume":"32","author":"Leroux-Roels","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.029_b0115","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/CVI.00807-13","article-title":"Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults","volume":"21","author":"Pauksens","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.02.029_b0120","doi-asserted-by":"crossref","first-page":"e59605","DOI":"10.1371\/journal.pone.0059605","article-title":"Characterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives","volume":"8","author":"Goulart","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.02.029_b0125","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/1040841X.2013.813902","article-title":"Current status and perspectives on protein-based pneumococcal vaccines","volume":"41","author":"Darrieux","year":"2015","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.vaccine.2017.02.029_b0130","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1473-3099(02)00182-2","article-title":"BCG\u2013different strains, different vaccines?","volume":"2","author":"Behr","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.02.029_b0135","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1016\/j.vaccine.2009.08.044","article-title":"Recombinant Mycobacterium bovis BCG","volume":"27","author":"Bastos","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.029_b0140","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2004.08.039","article-title":"Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines","volume":"23","author":"Dennehy","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.029_b0145","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/351456a0","article-title":"New use of BCG for recombinant vaccines","volume":"351","author":"Stover","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.02.029_b0150","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0264-410X(98)00276-X","article-title":"Safety and immunogenicity of recombinant Bacille Calmette-Guerin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine","volume":"17","author":"Edelman","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.029_b0155","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1128\/IAI.68.9.4877-4883.2000","article-title":"Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice","volume":"68","author":"Nascimento","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.02.029_b0160","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.1016\/j.vaccine.2012.05.083","article-title":"Generation of recombinant bacillus Calmette-Guerin and Mycobacterium smegmatis expressing BfpA and intimin as vaccine vectors against enteropathogenic Escherichia coli","volume":"30","author":"Vasconcellos","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.029_b0165","doi-asserted-by":"crossref","first-page":"11473","DOI":"10.1073\/pnas.90.24.11473","article-title":"Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63","volume":"90","author":"Connell","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.02.029_b0170","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1128\/IAI.72.6.3336-3343.2004","article-title":"Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge","volume":"72","author":"Varaldo","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.02.029_b0175","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1084\/jem.180.6.2277","article-title":"Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guerin vaccines expressing pneumococcal surface protein A","volume":"180","author":"Langermann","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.02.029_b0180","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1128\/JB.183.7.2157-2164.2001","article-title":"Genomic sequence and transcriptional analysis of a 23-kilobase mycobacterial linear plasmid: evidence for horizontal transfer and identification of plasmid maintenance systems","volume":"183","author":"Le Dantec","year":"2001","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2017.02.029_b0185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0378-1119(91)90587-2","article-title":"Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein","volume":"109","author":"Winter","year":"1991","journal-title":"Gene"},{"key":"10.1016\/j.vaccine.2017.02.029_b0190","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1128\/CVI.00430-13","article-title":"Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults","volume":"21","author":"Berglund","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2017.02.029_b0195","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1086\/313883","article-title":"Improving vaccine performance with adjuvants","volume":"30","author":"Vogel","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.02.029_b0200","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/vaccines2010049","article-title":"Development of Streptococcus pneumoniae Vaccines Using Live Vectors","volume":"2","author":"Wang","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2017.02.029_b0205","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1016\/j.vaccine.2013.07.049","article-title":"A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA","volume":"31","author":"Frey","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.029_b0210","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.vaccine.2010.12.074","article-title":"Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells","volume":"29","author":"Goulart","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.029_b0215","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1128\/CVI.00395-08","article-title":"Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice","volume":"16","author":"Ferreira","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.02.029_b0220","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1128\/IAI.69.11.6718-6724.2001","article-title":"Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection","volume":"69","author":"Arulanandam","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.02.029_b0225","doi-asserted-by":"crossref","first-page":"e10863","DOI":"10.1371\/journal.pone.0010863","article-title":"Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice","volume":"5","author":"Oliveira","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.02.029_b0230","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.micpath.2010.02.009","article-title":"Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A)","volume":"48","author":"Ferreira","year":"2010","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2017.02.029_b0235","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1128\/CVI.00171-12","article-title":"Controlled inflammatory responses in the lungs are associated with protection elicited by a pneumococcal surface protein A-based vaccine against a lethal respiratory challenge with Streptococcus pneumoniae in mice","volume":"19","author":"Lima","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.02.029_b0240","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1128\/JB.01489-08","article-title":"Pneumolysin localizes to the cell wall of Streptococcus pneumoniae","volume":"191","author":"Price","year":"2009","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2017.02.029_b0245","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.molimm.2015.06.019","article-title":"Trained immunity: a smart way to enhance innate immune defence","volume":"68","author":"Van der Meer","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2017.02.029_b0250","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000355628","article-title":"Long-lasting effects of BCG vaccination on both heterologous Th1\/Th17 responses and innate trained immunity","volume":"6","author":"Kleinnijenhuis","year":"2014","journal-title":"J Innate Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17302232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17302232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T23:12:55Z","timestamp":1656285175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17302232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":50,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0264410X17302232"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.02.029","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant BCG expressing a PspA-PdT fusion protein protects mice against pneumococcal lethal challenge in a prime-boost strategy","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}